Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

A new study has examined the effects of GLP-1 drugs on 175 different health outcomes. ​​​While these drugs have been found to ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...

Month-to-date it is up 0.36% vs the dollar --Year-to-date the euro is up 0.36% vs the dollar ...